Asundexian
- Generic Name
- Asundexian
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Phase 2
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Other: BAY2433334 matching placebo
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1601
- Registration Number
- NCT04304534
- Locations
- 🇺🇸
Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
🇺🇸Logan Health Research, Kalispell, Montana, United States
🇳🇱Reinier de Graaf Gasthuis, Delft, Netherlands
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
Phase 2
Completed
- Conditions
- Acute Non-cardioembolic Ischemic Stroke
- Interventions
- Other: BAY2433334 matching placebo
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1808
- Registration Number
- NCT04304508
- Locations
- 🇺🇸
Guilford Neurologic Associates, Greensboro, North Carolina, United States
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺John Hunter Hospital, New Lambton, New South Wales, Australia
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Phase 2
Completed
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 755
- Registration Number
- NCT04218266
- Locations
- 🇫🇷
Hôpital de Rangueil - Toulouse, Toulouse, France
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇸🇪Danderyds sjukhus, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath